Navigation Links
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
Date:5/20/2008

ist(TM) should

be used with caution in patients with cardiovascular disorders,

especially coronary insufficiency, cardiac arrythmias, and

hypertension.

Funding for these studies was provided by Dey, L.P., manufacturer and marketer of Perforomist(TM) (formoterol fumarate) Inhalation Solution. Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate. Formoterol fumarate is a rapid and long-acting beta(2)-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation with twenty years of worldwide experience. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or facemask.

"Taken together, these studies expand our understanding of the clinical benefits of Perforomist(TM) Inhalation Solution for the treatment of COPD," said Carolyn Myers, Ph.D., President of Dey, L.P. "Perforomist Inhalation Solution offers physicians a flexible, safe, and highly effective treatment option for COPD -- and many patients may benefit from this new addition to the treatment armamentarium."

About Perforomist(TM) Inhalation Solution

Indication

Perforomist(TM) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist(TM) Inhalation Solution belongs to a class of medications known as long-acting beta(2)-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
2. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
3. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
4. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
5. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
6. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...The Lancet, and Presented at ESC Congress-, PHILA...w international,study, the GISSI Heart Failure (GI...cid ethyl esters reduced all cause mortality and h...atients with chronic heart,failure. These findings...he,Lancet, and were presented at the European Card...
(Date:9/4/2008)...l Data for Ipilimumab to be Presented, PRINCETON,...Inc.,(Nasdaq: MEDX ) announced today that nine cl...l anti-CTLA-4 antibody, in melanoma are scheduled ...gress of the European Society,for Medical Oncology...olm.,Many of the following abstracts will include ...
(Date:9/3/2008)... Asked. Wrong Children Studied. Wrong,Conclusions ...re/ -- A Centers for Disease,Control and Preventio...nk,between the MMR vaccine and autism. The Nationa...thing to dispel the growing public concern over a,...ions concerning design,and methodology., For year...
(Date:9/3/2008)...ENEVA, Sept. 3 /- Artelis SA and,Sele...d monoclonal antibody,production with the achievem...iter. This record level was accomplished by applyi...performance stable Selexis CHO,production cell lin... at,Selexis SA using their proprietary Selexis Gen...
Breaking Medicine Technology:New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Stallergenes 3A Q2 2008 Sales up 18 25 Revision Upwards of 2008 Sales Growth 6493 1Stallergenes 3A Q2 2008 Sales up 18 25 Revision Upwards of 2008 Sales Growth 6493 2Link shown between thunderstorms and asthma attacks in metro Atlanta area 23729 1Link shown between thunderstorms and asthma attacks in metro Atlanta area 23729 2Link shown between thunderstorms and asthma attacks in metro Atlanta area 23729 3Melanoma Rates Soar Among Younger Women 23727 1Melanoma Rates Soar Among Younger Women 23727 2Melanoma Rates Soar Among Younger Women 23727 3Kidney Community Applauds Senate for Passage of End Stage Renal Disease 28ESRD 29 Improvements 23725 1Kidney Community Applauds Senate for Passage of End Stage Renal Disease 28ESRD 29 Improvements 23725 2
...ORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - Neurog...tive top-line,results from two dose-ranging, Phase...ith the Company,s proprietary insomnia agent,NG2-... Multiple,formulations were studied in each trial ...p onset and maintenance of sleep,through the night...
...OUTH MEETING, Pa., June 25, 2007 /PRNewswire-First...data from a preclinical,study of trodusquemine (MS...d during the American Diabetes Association (ADA) 6.... Dr. Kristen Lantz,Genaera research scientist an...dusquemine is a Multiple Pathway Inhibitor that,Ca...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
... as the striking doctors were determined to intens... and dry. All the government hospitals in Mumbai s... 2,500 doctors from 15 government-managed hospital...lion people have stayed away from work since Feb 2...
...e’s 26 day old baby from a Stroger Hospital clinic.... The woman is now in police custody. Aurelia Go...eared before Judge Raymond Myles of the criminal c...Gonzalez sought permission from the baby’s father ...
...a 70 % minimum requirement in the HSC examinations...ission to medical// and dental colleges in the ope...t 60 % of the weightage for admission in medical a... marks. In case of common entrance test (CET), the...
...Leicester Royal Infirmary in 2001 who wrongly diag...allenging a decision ordering him to retrain.// T... of epilepsy to 618 children in Leicestershire bet...uary the General Medical Council ruled that his pe...
Other Medicine News:Health News:Health Services Came To A Halt As Mumbai Doctors Strike Continues 2
The MD Coder is simply more than a reference guide: it is a handheld solution for accurate coding and patient tracking for both individual physicians and small practice groups. MD Coder v6.0 now come
Integrated patient tracking and billing. This product contains the complete Handheld application, a complete Desktop application, and complete CPT™ and ICD-9-CM codes licensed from the AMA. Desi
PharmD ToolBox is an advanced medical calculator and rapid reference for Emergency, Pediatric Dosing and Critical Care for PharmDs. This product is a logical complement to other PDA reference product
iFacts™ is the handheld version of Drug Interaction Facts, a drug interaction analyzer covering thousands of brand and generic drugs. iFacts™ enables the practitioner to refer to accurate a
Medicine Products: